News

Role of SES in childhood cancer survival disparities


 

Photo by Bill Branson

Child with cancer

Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research.

The study showed that whites had a significant survival advantage over blacks and Hispanics for several childhood cancers.

SES significantly mediated the association between race/ethnicity and survival for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma, and non-Hodgkin lymphoma (NHL).

Rebecca Kehm, PhD, of Columbia University in New York, New York, and her colleagues reported these findings in Cancer alongside a related editorial.

The researchers examined population-based cancer survival data from the Surveillance, Epidemiology, and End Results database.

The team collected information on 31,866 patients, ages 0 to 19, who were diagnosed with cancer between 2000 and 2011.

Survival differences by race/ethnicity

The researchers found that whites had a significant survival advantage over blacks for the cancers listed in the following table.

Survival—black vs white
CancerMortality hazard ratio95% confidence intervalP value
ALL1.431.15-1.77<0.01
AML1.681.36-2.07<0.001
Neuroblastoma1.381.08-1.750.01
NHL1.531.14-2.070.01
Hodgkin lymphoma1.661.06-2.600.03
Astrocytoma1.951.57-2.43<0.001
Non-astrocytoma CNS tumor1.531.25-1.88<0.001
Non-rhabdomyosarcoma STS1.401.06-1.840.02
Rhabdomyosarcoma1.441.10-1.880.01

In addition, whites had a significant survival advantage over Hispanics for the following cancers.

Survival—Hispanic vs white
CancerMortality hazard ratio95% confidence intervalP value
ALL1.631.43-1.86<0.001
Neuroblastoma1.311.04-1.650.02
NHL1.651.29-2.12<0.001
Astrocytoma1.341.10-1.64<0.01
Wilms tumor1.601.04-2.450.03
Germ cell tumor1.631.19-2.24<0.01

Impact of SES

SES significantly mediated the association between race/ethnicity and survival for ALL, AML, neuroblastoma, and NHL but not for Hodgkin lymphoma or other cancers.

For black versus white patients, SES reduced the original association between race/ethnicity and survival by:

  • 44% for ALL
  • 28% for AML
  • 49% for neuroblastoma
  • 34% for NHL.

For Hispanics versus whites, SES reduced the original association between race/ethnicity and survival by:

  • 31% for ALL
  • 73% for AML
  • 48% for neuroblastoma
  • 28% for NHL.

“These findings provide insight for future intervention efforts aimed at closing the survival gap,” Dr Kehm said.

“For cancers in which socioeconomic status is a key factor in explaining racial and ethnic survival disparities, behavioral and supportive interventions that address social and economic barriers to effective care are warranted. However, for cancers in which survival is less influenced by socioeconomic status, more research is needed on underlying differences in tumor biology and drug processing.”

This research was supported by a grant from the National Institutes of Health, and the study’s authors made no disclosures.

Recommended Reading

Immunotherapies shape the treatment landscape for hematologic malignancies
MDedge Hematology and Oncology
First CAR T-cell therapy approvals bolster booming immunotherapy market
MDedge Hematology and Oncology
Lenalidomide best option for myeloma maintenance therapy
MDedge Hematology and Oncology
FDA puts partial hold on trial of vascular agent for AML, MDS
MDedge Hematology and Oncology
Inhibitor receives orphan designation for AML
MDedge Hematology and Oncology
Partial hold placed on trial of drug for AML, MDS
MDedge Hematology and Oncology
Access to care drives disparity between urban, rural cancer patients
MDedge Hematology and Oncology
Drug under priority review for BPDCN
MDedge Hematology and Oncology
Study links communication, outcomes in cancer
MDedge Hematology and Oncology
Auto-HSCT linked to higher AML, MDS risk
MDedge Hematology and Oncology